← Leaderboards
Nima Sharifi
University Of Miami School Of Medicine
$12,617,877
Attributed
$13,824,159
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,824,159 · 7
By mechanism
R01$13,664,922 · 6
P30$159,237 · 1
Top collaborators
- Susan Halabi4 shared
- Charles James Ryan2 shared
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Kerry L. Burnstein$4,138,515
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateTumorEnzymesResistanceAndrogensCessation Of LifeStanoloneHydroxysteroid DehydrogenasesResponseCastration Resistant Prostate CancerAbirateroneCancer EtiologyHormone TherapyAndrogen ReceptorTestosteroneSteroidsCastrationMetabolicAndrogen Deprivation TherapyMedical CastrationAdrenal GlandsClinical ResearchInhibitor/AntagonistUnited States
Grant awards (44)
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$422,125
R01 · FY2025 · CA · contact PI
CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapy$351,131
R01 · FY2025 · CA · contact PI
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer$523,041
R01 · FY2024 · CA
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$401,019
R01 · FY2024 · CA · contact PI
CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapy$333,575
R01 · FY2024 · CA · contact PI
Aberrant tumor metabolism that enables AR antagonist-resistant prostate cancer$333,575
R01 · FY2024 · CA · contact PI
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer$466,468
R01 · FY2023 · CA
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$422,125
R01 · FY2023 · CA · contact PI
CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapy$283,247
R01 · FY2023 · CA · contact PI
Aberrant tumor metabolism that enables AR antagonist-resistant prostate cancer$274,080
R01 · FY2023 · CA · contact PI
Aberrant tumor metabolism that enables AR antagonist-resistant prostate cancer$73,450
R01 · FY2023 · CA · contact PI
CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapy$63,835
R01 · FY2023 · CA · contact PI
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer$640,563
R01 · FY2022 · CA
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$374,728
R01 · FY2022 · CA · contact PI
CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapy$368,288
R01 · FY2022 · CA · contact PI
Aberrant tumor metabolism that enables AR antagonist-resistant prostate cancer$360,922
R01 · FY2022 · CA · contact PI
GU Malignancies Research Program$55,093
P30 · FY2022 · CA · contact PI
Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer$426,729
R01 · FY2021 · CA
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$382,375
R01 · FY2021 · CA · contact PI
Aberrant tumor metabolism that enables AR antagonist-resistant prostate cancer$368,288
R01 · FY2021 · CA · contact PI
GU Malignancies Research Program$53,114
P30 · FY2021 · CA · contact PI
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$381,781
R01 · FY2020 · CA · contact PI
Aberrant tumor metabolism that enables AR antagonist-resistant prostate cancer$366,954
R01 · FY2020 · CA · contact PI
GU Malignancies Research Program$51,030
P30 · FY2020 · CA · contact PI
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$368,600
R01 · FY2019 · CA · contact PI
Compensatory steroidogenesis mechanisms in castration-resistant prostate cancer$351,691
R01 · FY2019 · CA · contact PI
Compensatory steroidogenesis mechanisms in castration-resistant prostate cancer$86,813
R01 · FY2019 · CA · contact PI
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$380,000
R01 · FY2018 · CA · contact PI
Compensatory steroidogenesis mechanisms in castration-resistant prostate cancer$362,569
R01 · FY2018 · CA · contact PI
Compensatory steroidogenesis mechanisms in castration-resistant prostate cancer$89,498
R01 · FY2018 · CA · contact PI
Compensatory steroidogenesis mechanisms in castration-resistant prostate cancer$362,569
R01 · FY2017 · CA · contact PI
Cooperative steroidogenic inhibition for treatment of advanced prostate cancer$326,897
R01 · FY2017 · CA · contact PI
Compensatory steroidogenesis mechanisms in castration-resistant prostate cancer$74,371
R01 · FY2017 · CA · contact PI
Compensatory steroidogenesis mechanisms in castration-resistant prostate cancer$362,569
R01 · FY2016 · CA · contact PI
Cooperative steroidogenic inhibition for treatment of advanced prostate cancer$326,897
R01 · FY2016 · CA · contact PI
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$322,844
R01 · FY2016 · CA · contact PI
Compensatory steroidogenesis mechanisms in castration-resistant prostate cancer$362,569
R01 · FY2015 · CA · contact PI
Cooperative steroidogenic inhibition for treatment of advanced prostate cancer$326,897
R01 · FY2015 · CA · contact PI
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$325,745
R01 · FY2015 · CA · contact PI
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$319,021
R01 · FY2014 · CA · contact PI
Cooperative steroidogenic inhibition for treatment of advanced prostate cancer$317,090
R01 · FY2014 · CA · contact PI
Cooperative steroidogenic inhibition for treatment of advanced prostate cancer$340,899
R01 · FY2013 · CA · contact PI
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$309,159
R01 · FY2013 · CA · contact PI
Elucidating a novel molecular biomarker for castration-resistant prostate cancer$329,925
R01 · FY2012 · CA · contact PI